Analyst Price Targets — LUCD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 15, 2026 12:46 pm | — | Maxim Group | $2.00 | $0.99 | TheFly | Lucid Diagnostics price target lowered to $2 from $3 at Maxim |
| March 25, 2025 11:25 am | — | BTIG | $2.00 | $1.55 | TheFly | Lucid Diagnostics price target lowered to $2 from $2.50 at BTIG |
| November 13, 2024 5:31 pm | Mike Matson | Needham | $2.50 | $0.79 | StreetInsider | Needham Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD) |
| May 14, 2024 8:01 am | Kyle Mikson | Canaccord Genuity | $3.00 | $0.95 | StreetInsider | Canaccord Genuity Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD) |
| April 8, 2024 7:51 am | Mark Massaro | BTIG | $2.50 | $0.93 | StreetInsider | BTIG updates Lucid Diagnostics Inc (LUCD) model post Q4 results |
| November 18, 2022 7:52 am | — | BTIG | $3.50 | $1.91 | Benzinga | BTIG Maintains Buy on Lucid Diagnostics, Lowers Price Target to $3.5 |
| November 15, 2022 5:49 am | — | Needham | $3.10 | $2.27 | Benzinga | Needham Maintains Buy on Lucid Diagnostics, Lowers Price Target to $3.1 |
Latest News for LUCD
Lucid Diagnostics NASDAQ: LUCD is positioning its EsoGuard test as a non-invasive tool to identify Barrett's Esophagus, a precancerous condition associated with esophageal cancer, while it awaits a key Medicare coverage decision and expands relationships with commercial payers, the Department of Veterans Affairs and health systems.
Veris Health accelerated its commercial engagement with OSU-The James Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ® Conference call and webcast to be held today, August 14, at 8:30 AM EDT NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed"…
Lucid Diagnostics Inc. (LUCD) Q2 2026 Earnings Call Transcript
Lucid Diagnostics NASDAQ: LUCD reported second-quarter revenue of $1.5 million on 2,770 EsoGuard tests, as the company continued to target quarterly test volume of roughly 2,500 to 3,000 tests while awaiting a Medicare draft local coverage determination, or LCD.
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.1 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LUCD.
U.S. House Trading
No House trades found for LUCD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.